Alfred E. Tiefenbacher (GmbH & Co. GmbH) Germany

Ms Anna Bettina Goos
Business Development & Licensing Manager 

Alliance Pharmaceuticals GmbH Germany

Mr Lars Börger
General Manager D/A/CH 

Bannert Manlik Consultants GmbH Germany

Specialized Pharma M&A Boutique operating since 1991 globally

Ms Ulrike Däxl
Ms Ulrike Däxl
Project Manager 
Mr Mathias Käsebier
Mr Mathias Käsebier
LinkedIn logo Senior Director 

Bayer AG Germany

Dr Ulrich Koch
VP BD&L Negotiations 

Boehringer Ingelheim Corporate Center GmbH Germany

Mr Juergen Beck
Head of Strategic Transactions & Alliance Management 

Brueckner-IP Germany

IP Law Firm

Dr Christopher Brueckner
Patent Attorney 

Dr. M. Newzella GmbH Germany

Dr. M. Newzella GmbH is an international personnel and business consulting company active within the fields of pharmaceuticals and health care and specializing in the areas of Executive Search, Merger & Acquisition and Product & Licensing.

Thanks to its 35 years of branch experience, Dr. Newzella Consulting has built up an extensive international network of excellent business contacts and has far-reaching knowledge of both companies and markets to supports its clients with individual, flexible and high performance services.

Dr Christoph Newzella
Dr Christoph Newzella
Managing Partner & Director Management Consulting 
Dr Matthias Newzella
Dr Matthias Newzella
Managing Partner, Director Management Consulting & Head of Executive Search 

Dr. Willmar Schwabe GmbH & Co KG Germany

Cornel Martin
Head of Business Development & Licensing 

Fair-Med Healthcare GmbH Germany

Dr Albert Schaper
Managing Director 

GeneriNobel GmbH Germany

GeneriNobel is a privately owned pharmaceutical company, based in Germany, which outlicenses generic drugs (Rx) and OTC developments for the European market.

Key therapeutic areas are cardiovascular diseases, central nervous system and metabolism. GeneriNobel has a focus on dossier development, registration and outlicensing of generic / OTC drugs and represents the marketing authorization / dossier portfolio of its partner, the turkish multinational pharmaceutical company Nobel Ilaç (own R&D and manufacturing of APIs and finished products).

We offer:

* Out-licensing of generic / OTC drugs (dossiers) at an advanced stage of regulatory approval procedure, e. g. Rosuvastatin.

* Out-licensing of generic / OTC drugs (marketing authorisations / dossiers) with granted marketing authorisations in Germany and which are available for further registration procedures in Europe, e. g. Solifenacin, Rasagiline, Duloxetine, Aripiprazole, Memantine, Irbesartan and Irbesartan-HCTZ, Sildenafil, Escitalopram, Pantoprazole and Omeprazole.

We are interested in:

Marketing and Sales companies who are interested to in-license products of our Portfolio.

We are NOT interested in:

* regulatory service providers, IP service providers, legal advisors, APIs.

Dr Wolfgang Bäurle
Managing Director